Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Large Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 240,400 shares, an increase of 450.1% from the December 15th total of 43,700 shares. Based on an average daily volume of 2,980,000 shares, the short-interest ratio is presently 0.1 days. Currently, 2.9% of the company’s shares are sold short.

Revelation Biosciences Stock Down 5.5 %

REVB traded down $0.03 during trading hours on Monday, reaching $0.50. 397,511 shares of the company’s stock traded hands, compared to its average volume of 16,594,914. The firm has a 50-day moving average price of $0.60 and a 200 day moving average price of $0.97. Revelation Biosciences has a 52-week low of $0.28 and a 52-week high of $25.26. The firm has a market capitalization of $2.15 million, a PE ratio of -0.03 and a beta of 0.24.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.